title: Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone.
abstract: Approximately 50% of neurofibromatosis type 1 (NF1) patients exhibit skeletal pathology, such as premature osteoporosis or pseudoarthroses. Loss of neurofibromin deregulates Ras signal transduction to affect generation of mitogen-activated protein kinase and Akt, both of which have been implicated in parathyroid hormone (PTH) anabolic mechanisms. Our aim was to determine if loss of neurofibromin impaired the anabolic effect of PTH on bone mass. Nf1 heterozygote (Nf1(+/-)) and wild type (Nf1(+/+)) mice were treated with recombinant human PTH(1-34) or vehicle once daily for 3-28 days. PTH enhanced mRNA expression of c-fos, junB, and fra2 in the distal femur metaphyses of both genotypes; expression of these transcripts was consistently lower in PTH-treated Nf1(+/-) mice. Despite lowered c-fos expression in Nf1(+/-) mice, PTH increased bone mass equivalently in both genotypes by 28 days. Ex vivo, Nf1 heterozygosity was associated with increased inducible osteoclasts in PTH-treated bone marrow cells and impairment of the actin stress fiber and cyclic adenosine monophosphate response to PTH in osteoprogenitors. Lower c-fos expression was previously thought to abrogate PTH responsiveness. Our results suggest crosstalk might occur between Ras signal transduction and the protein kinase A pathway in Nf1(+/-) mice. Ras signal transduction does not appear to be essential for the anabolic actions of PTH on bone. Because PTH was effective in the absence of Nf1, it may offer a useful approach to treat osteoporosis in NF1 patients.
authors.affiliation: Department of Anatomy and Cell Biology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA. xijyu@iupui.edu
authors.forename: X
authors.initials: X
authors.lastname: Yu
authors.forename: J
authors.initials: J
authors.lastname: Milas
authors.forename: N
authors.initials: N
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Rao
authors.forename: S
authors.initials: S
authors.lastname: Murthy
authors.forename: O L
authors.initials: OL
authors.lastname: Potter
authors.forename: M J
authors.initials: MJ
authors.lastname: Wenning
authors.forename: W D
authors.initials: WD
authors.lastname: Clapp
authors.forename: J M
authors.initials: JM
authors.lastname: Hock
mesh_terms: D000135:Acid Phosphatase / Q000378:metabolism; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000032:analysis; D005269:Femur / Q000378:metabolism / Q000601:surgery; D015870:Gene Expression; D016514:Genes, Neurofibromatosis 1; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010281:Parathyroid Hormone / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D012260:Ribonucleases / Q000096:biosynthesis; D000071681:Tartrate-Resistant Acid Phosphatase; D013977:Tibia / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D018808:Transcription Factor AP-1 / Q000235:genetics*
chemical_list: D007527:Isoenzymes; D010281:Parathyroid Hormone; D012333:RNA, Messenger; D011994:Recombinant Proteins; D018808:Transcription Factor AP-1; D000242:Cyclic AMP; D012260:Ribonucleases; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase